When a woman takes estrogen, the effects depend on why she’s taking it, how it’s delivered, and where she is in life. For menopausal women, estrogen can reduce hot flashes by 70 to 95% within the first month. For transgender women, it triggers gradual physical feminization over two to five years. In both cases, estrogen acts on nearly every organ system in the body, producing changes that range from immediate side effects like breast tenderness to long-term shifts in bone density, cardiovascular health, and cancer risk.
What Estrogen Does in the Body
Estrogen isn’t a single-purpose hormone. It has receptors in the reproductive tract, urinary tract, heart and blood vessels, bones, breasts, skin, hair, brain, and pelvic muscles. When you introduce additional estrogen, whether through a pill, patch, or gel, it activates those receptors throughout the body. That’s why the effects are so wide-ranging and why the same hormone can simultaneously relieve hot flashes, strengthen bones, and change how your skin feels.
Early Side Effects
Most women experience some side effects when they first start estrogen. Common ones include headaches, breast pain or tenderness, nausea, mood changes (including low mood), unexpected vaginal bleeding, leg cramps, mild rash, and sometimes hair thinning. These tend to improve within a few weeks as your body adjusts. The general recommendation is to stick with treatment for at least three months before deciding whether the side effects are tolerable, since most resolve on their own in that window.
Relief From Menopausal Symptoms
Hot flashes are the most common reason menopausal women take estrogen, and the relief is substantial. A meta-analysis of randomized trials found that oral and transdermal estrogen reduced hot flashes by 70 to 95% within one month of starting treatment. That’s a dramatic improvement compared to non-hormonal alternatives: gabapentin, for instance, reduces hot flashes by about 35%.
Estrogen also helps with vaginal dryness, urinary discomfort, and the thinning of tissues in the genital and urinary tract that happens after menopause. These changes occur because estrogen maintains the moisture and elasticity of those tissues, and without it, they gradually become thinner and more fragile.
Effects on Bone Strength
One of estrogen’s most important roles is maintaining bone density. After menopause, when natural estrogen levels drop sharply, women lose bone mass rapidly, which is why osteoporosis disproportionately affects postmenopausal women. Taking estrogen counteracts this.
The Women’s Health Initiative, which followed over 25,000 postmenopausal women, found that hormone therapy reduced the risk of any clinical fracture by 28%, major osteoporotic fractures by 40%, and hip fractures by 34%. These reductions held regardless of a woman’s baseline fracture risk or history of falls. For women at risk of osteoporosis, this is one of estrogen’s clearest, most well-documented benefits.
Cardiovascular Effects and Timing
Estrogen’s relationship with heart health is complicated, and timing matters enormously. There’s a “window of opportunity”: women who start estrogen before age 60, or within 10 years of menopause, may see neutral or even protective cardiovascular effects. But starting estrogen later in life, especially in oral form, substantially increases the risk of ischemic stroke.
Because of this age-dependent effect, hormone therapy is not recommended for the purpose of preventing heart disease at any age. The cardiovascular benefits, if they exist, appear to be a secondary effect of starting treatment early for symptom relief, not a reason to start treatment on their own.
Blood Clot Risk
Estrogen increases the risk of blood clots. In studies of women on hormone therapy, about 2 in every 1,000 women per year experienced a venous blood clot. That’s a small absolute number, but it’s higher than the baseline risk for women not taking estrogen.
One finding that may surprise you: a study of women Veterans found no meaningful difference in clot risk between oral estrogen and transdermal estrogen (patches or gels). This contrasts with some earlier research suggesting patches were safer. The delivery method does differ in other ways, though. Oral estrogen passes through the liver before reaching the rest of the body, which affects cholesterol levels and the production of certain liver proteins. Transdermal estrogen bypasses the liver entirely, which is why it has less impact on blood lipid profiles. Oral estrogen also has low systemic bioavailability, only 2 to 10%, because the liver breaks down so much of it on the first pass.
Breast Cancer Risk
The breast cancer picture depends heavily on whether estrogen is taken alone or combined with a progestogen. In the Women’s Health Initiative, women who had previously had a hysterectomy and took estrogen alone actually had a lower breast cancer risk than women on placebo, with a 23% reduction after about 10 years of follow-up. The absolute risk was 43 cases per 10,000 person-years.
The combination of estrogen plus a progestogen, which is necessary for women who still have a uterus (to prevent uterine lining overgrowth), tells a different story. That combination is associated with a modest increase in breast cancer risk, which is one reason the type of hormone therapy prescribed differs based on whether a woman has had a hysterectomy.
Effects on Memory and Cognition
Before large clinical trials, observational studies suggested estrogen might reduce Alzheimer’s risk by nearly 40%. The Women’s Health Initiative Memory Study upended that assumption. In women aged 65 and older, estrogen combined with a progestogen roughly doubled the risk of dementia. Estrogen alone increased it by about half. The combination also worsened verbal memory, while estrogen alone had no significant effect on cognition.
There’s an ongoing debate about whether these findings apply to younger women who start estrogen closer to menopause. The “critical window” hypothesis suggests that estrogen might protect the brain if started early but harm it if started late. Some observational data supports this idea, but no randomized trial has confirmed it. The current evidence does not support taking estrogen at any age specifically to prevent cognitive decline.
Physical Changes in Feminizing Hormone Therapy
For transgender women, estrogen produces a distinct set of physical changes. These include breast development (typically reaching a moderate stage), redistribution of fat from the abdomen toward the hips, thighs, and face, reduction in muscle mass, thinning of body hair, changes in sweat and body odor, and slowing or partial reversal of scalp hair loss. Facial hair reduction tends to be less dramatic than body hair changes.
These changes are gradual. Most sources suggest that maximal feminization occurs over two to five years, though the timeline varies considerably between individuals. Breast development and fat redistribution are among the slowest changes, while skin softening and changes in body odor tend to happen earlier. Comparing your own timeline to others’ experiences is generally unhelpful, since genetics play a large role in how the body responds.
How Delivery Method Matters
Estrogen comes in several forms: pills, skin patches, gels, sprays, and vaginal preparations. Each reaches the body differently. Oral estrogen is heavily metabolized by the liver, so only a small fraction (2 to 10%) reaches the bloodstream intact. This first-pass metabolism produces high levels of estrone, a weaker form of estrogen, and stimulates liver proteins that affect clotting and cholesterol. Transdermal options bypass the liver entirely, delivering estradiol (the body’s primary estrogen) more directly into the bloodstream. Vaginal products are applied locally but can still achieve significant blood levels.
For women who need only local relief from vaginal dryness or urinary symptoms, low-dose vaginal estrogen is often preferred because it treats the area directly with minimal whole-body exposure. For systemic symptoms like hot flashes and bone loss, oral or transdermal options are standard, with transdermal forms sometimes favored for women with higher cardiovascular or liver-related risk factors.